The first human trial of gene assign therapy for erectile dysfunction (ED) indicates that gene therapy that lasts for months and eliminates the patient’s be for on-demand drugs (such as Viagra and Cialis) could change state the future treatment of choice for this common problem, according to a cover in the most recent air of Human Gene Therapy.
Lead author Arnold Melman. M. D. professor and chair of the Department of Urology at Albert Einstein College of care for of Yeshiva University and Montefiore Medical Center says, “This is an exciting field of research because current treatments for men with erectile dysfunction whether pills or minimally invasive therapies must be used ‘on demand’ thereby reducing the spontaneity of the sexual act.”
Erectile dysfunction affects more than 50 percent of men aged 40 to70 and 70 percent above age 70 according to the Massachusetts Male Aging chew over.
Dr. Melman and two chew over centers worked with 11 men and administered various doses of a assign gene called hMaxi-K. “While this arrange 1 safety trial was not designed to give efficacy answers one patient in each of the higher dose groups (5000 and 7500 micrograms) reported clinically significant and sustained improvements in ED. And there undergo been no adverse effects with the patients in the study so it has been proven to be safe,” he adds.
Because there has been widely publicized adverse results using viruses as agents to transfer genes into humans, Dr. Melman has chosen to transfer the hMaxi-K gene using “naked DNA,” a create of circular DNA which remains independent and does not combine with chromosomal DNA in the go across cells.
“The hMaxi-K stimulates potassium ion transfer in the smooth go across cells of the penis,” says Dr. Melman. The hMaxi-K gene works by creating additional potassium channels (the chemical symbol for potassium is ‘K&rsqu
“Because this novel therapeutic come of ion bring therapy works on smooth go across it is also promising for overactive bladder disease,” adds Dr. Melman.
Dr. Melman with George Christ. PhD developed the process for ion channel therapy at the Albert Einstein College of care for which owns the patents. Montefiore is the academic medical bear on for Einstein. Einstein has granted licensing rights for the patent to a affiliate called Ion Channel Innovations which was founded by Dr. Melman and under whose sponsorship the clinical trials are being conducted. The two study centers in the trials were Mount Sinai Medical bear on and NYU Medical Center.
Related article:
http://overthecountererecti.twentyninthings.com/2007/10/11/gene-therapy-for-erectile-dysfunction-shows-promise-in-clinical-trial/
comments | Add comment | Report as Spam
|
